代谢相关脂肪性肝病诊断与治疗研究进展  

Research Advances in Diagnosis and Treatment of Metabolic-Associated Fatty Liver Disease

作　　者：王子金 李学锋[1] 向明钧[2] 欧芳波 WANG Zijin;LI Xuefeng;XIANG Mingjun;OU Fangbo(Department of Gastroenterology,The First Affiliated Hospital of Jishou University,Jishou 416000,Hunan China;School of Medicine,Jishou University,Jishou 416000,Hunan China)

机构地区：[1]吉首大学第一附属医院消化科,湖南吉首416000 [2]吉首大学医学院,湖南吉首416000

出　　处：《吉首大学学报（自然科学版）》2022年第4期81-86,共6页Journal of Jishou University(Natural Sciences Edition)

摘　　要：代谢相关脂肪性肝病是目前世界上最常见的慢性肝病,也是我国第一大肝病.其发病率呈逐年上升趋势,肝脏脂肪变性程度的加重,增加了肝脏纤维化、肝硬化甚至肝癌的发病率,严重危害人们的身体健康.近年来在MAFLD的诊断及治疗方面发生了许多新变化,已成为研究热点.本研究从脂肪肝的全球危害及卫生负担、脂肪肝命名的变迁、代谢相关脂肪性肝病的诊断与治疗几个方面展开综述,以期为代谢相关脂肪性肝病的早期诊断、病情评估、新药研发等提供参考.Metabolic-associated fatty liver disease(MAFLD) is the most common chronic liver disease in the world and also the number one liver disease in China.Its incidence rate shows an upward trend year by year.If the degree of liver steatosis is aggravated, liver fibrosis may occur and eventually lead to liver cirrhosis and even hepatocarcinoma.All these are serious hazards to people’s health.In recent years, many new changes have taken place in the diagnosis and treatment of MAFLD,which has become a research hotspot.This article reviews the global harm and health burden of fatty liver disease, the change of fatty liver naming and the diagnosis and treatment of metaboli-associated fatty liver disease.The purpose of this study is to provide reference for the early diagnosis, disease evaluation and new drug development of metabolic-associated fatty liver disease.

关 键 词：代谢相关脂肪性肝病 非酒精性脂肪性肝病 诊断 治疗 

分 类 号：R575[医药卫生—消化系统]